tiprankstipranks
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
US Market
BBOT
BridgeBio Oncology Therapeutics
RESEARCH TOOLSreports
Want to see BBOT full AI Analyst Report?

BridgeBio Oncology Therapeutics (BBOT) Stock News & Sentiment

57 Followers
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
Premium
Company Announcements
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
7d ago
BBOT
Analyst Reiterates Buy on BridgeBio Oncology Therapeutics with Unchanged $29 12-Month Price Target Amid Promising Pan-KRAS Pipeline
Premium
Ratings
Analyst Reiterates Buy on BridgeBio Oncology Therapeutics with Unchanged $29 12-Month Price Target Amid Promising Pan-KRAS Pipeline
20d ago
BBOT
BridgeBio Oncology Overhauls Leadership for Next Development Phase
Premium
Company Announcements
BridgeBio Oncology Overhauls Leadership for Next Development Phase
28d ago
8K
BBOT
3 Best Stocks to Buy Today, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, According to Top Analysts
1M ago
BBOT
VSTM
BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility
Premium
Company Announcements
BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility
3M ago
BBOT
Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
Premium
Ratings
Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
4M ago
BBOT
BridgeBio Oncology reports promising RAS and PI3Kα data
Premium
Company Announcements
BridgeBio Oncology reports promising RAS and PI3Kα data
4M ago
8K
BBOT
More BBOT News >

BBOT News on the Web

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter | The Motley Fool
Motley Fool
Neutral
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally | The Motley Fool
Motley Fool
Neutral
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More | The Motley Fool
Motley Fool
Neutral
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet | The Motley Fool
Motley Fool
Neutral
Morgan Stanley Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arvinas Holding Company (ARVN) and BridgeBio Oncology Therapeutics (BBOT)
TipRanks News
Bullish
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
TipRanks News
Bearish
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Century Therapeutics (IPSC)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
BBOT
Sector Average
Media Buzz
This Week5 articles
Weekly Average4.75 articles
News Sentiment
This Week100%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BBOT’s Media Buzz Sentiment?
5 articles about BBOT were published this week. In an average week, 4.75 articles are published.
    What is BBOT’s weekly average amount of articles?
    In an average week, 4.75 articles about BBOT are published.
      What is BBOT’s News Sentiment?
      100% of articles about BBOT were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        IMVTImmunovant
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week